ATE266022T1 - Imidazol derivate als raf kinase inhibitoren - Google Patents

Imidazol derivate als raf kinase inhibitoren

Info

Publication number
ATE266022T1
ATE266022T1 AT01907974T AT01907974T ATE266022T1 AT E266022 T1 ATE266022 T1 AT E266022T1 AT 01907974 T AT01907974 T AT 01907974T AT 01907974 T AT01907974 T AT 01907974T AT E266022 T1 ATE266022 T1 AT E266022T1
Authority
AT
Austria
Prior art keywords
sub
sup
alkyl
optionally substituted
hydrogen
Prior art date
Application number
AT01907974T
Other languages
English (en)
Inventor
Jon Graham Steadman
Andrew Kenneth Takle
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0005387A external-priority patent/GB0005387D0/en
Priority claimed from GB0005370A external-priority patent/GB0005370D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE266022T1 publication Critical patent/ATE266022T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01907974T 2000-03-06 2001-03-02 Imidazol derivate als raf kinase inhibitoren ATE266022T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0005387A GB0005387D0 (en) 2000-03-06 2000-03-06 Compounds
GB0005370A GB0005370D0 (en) 2000-03-06 2000-03-06 Compounds
PCT/GB2001/000908 WO2001066539A1 (en) 2000-03-06 2001-03-02 Imidazol derivatives as raf kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE266022T1 true ATE266022T1 (de) 2004-05-15

Family

ID=26243806

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01907974T ATE266022T1 (de) 2000-03-06 2001-03-02 Imidazol derivate als raf kinase inhibitoren

Country Status (8)

Country Link
US (2) US7235658B2 (de)
EP (1) EP1263753B1 (de)
JP (1) JP2003525936A (de)
AT (1) ATE266022T1 (de)
AU (1) AU2001235838A1 (de)
DE (1) DE60103136T2 (de)
ES (1) ES2218391T3 (de)
WO (1) WO2001066539A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1529901A (en) * 1999-11-22 2001-06-04 Smithkline Beecham Plc Compounds
ATE266022T1 (de) * 2000-03-06 2004-05-15 Smithkline Beecham Plc Imidazol derivate als raf kinase inhibitoren
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121488D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
US20040192689A1 (en) * 2001-09-05 2004-09-30 Dean David Kenneth Heterocycle-carboxamide derivatives as raf kinase inhibitors
WO2003022832A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans and pyrroles as raf kinase inhibitors
WO2003082272A1 (en) * 2002-03-29 2003-10-09 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
WO2004019873A2 (en) 2002-08-29 2004-03-11 Scios Inc. Methods of promoting osteogenesis
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
WO2005030091A2 (en) 2003-09-25 2005-04-07 Scios Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
KR20060118472A (ko) 2003-10-16 2006-11-23 카이론 코포레이션 치환 벤자졸 및 ｒａｆ 키나아제의 저해제로서 그것의 사용
US20050282909A1 (en) * 2003-11-14 2005-12-22 Diks Sander H Guanylhydrazones in methods of treatment or diagnosis as modulators of signal transduction
US7250434B2 (en) 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
EP1676574A3 (de) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Verfahren zur Förderung des Überlebens von Zell- und Gewebe-Transplantaten
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2181987B9 (de) 2007-08-23 2014-09-03 Takeda Pharmaceutical Company Limited 2-Carbonylaminobenzothiazole und ihre Verwendung zur Vorbeugung und Behandlung von Krebs
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
EP3969449B1 (de) 2019-05-13 2025-02-12 Novartis AG Neue kristalline formen von n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluormethyl)isonicotinamid als raf-inhibitoren zur behandlung von krebs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR75287B (de) * 1980-07-25 1984-07-13 Ciba Geigy Ag
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
KR19990064117A (ko) * 1995-10-06 1999-07-26 폴락 돈나 엘. 항암 활성과 사이토킨 억제 활성을 갖는 치환된 이미다졸
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
ES2239357T3 (es) 1996-06-10 2005-09-16 MERCK & CO., INC. Imidazoles sustituidos que tienen actividad inhibidora de citoquinas.
CN1213022C (zh) 1997-12-22 2005-08-03 拜尔有限公司 用对称和不对称的取代二苯脲抑制raf激酶
JP2002516322A (ja) 1998-05-22 2002-06-04 スミスクライン・ビーチャム・コーポレイション 新規２−アルキル置換イミダゾール化合物
US6691178B1 (en) * 2000-02-22 2004-02-10 Stmicroelectronics, Inc. Fencepost descriptor caching mechanism and method therefor
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
ATE266022T1 (de) 2000-03-06 2004-05-15 Smithkline Beecham Plc Imidazol derivate als raf kinase inhibitoren
US7199137B2 (en) 2000-09-21 2007-04-03 Smithkline Beecham Plc Imidazole derivatives as Raf kinase inhibitors
ATE365730T1 (de) 2000-11-20 2007-07-15 Smithkline Beecham Corp Neuartige verbindungen
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121490D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
US20040192689A1 (en) 2001-09-05 2004-09-30 Dean David Kenneth Heterocycle-carboxamide derivatives as raf kinase inhibitors
WO2003022832A1 (en) 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans and pyrroles as raf kinase inhibitors
US7375105B2 (en) 2001-09-05 2008-05-20 Smithkline Beecham P.L.C. Pyridine substituted furan derivatives as Raf kinase inhibitors

Also Published As

Publication number Publication date
AU2001235838A1 (en) 2001-09-17
DE60103136D1 (de) 2004-06-09
WO2001066539A1 (en) 2001-09-13
EP1263753B1 (de) 2004-05-06
US20060122207A1 (en) 2006-06-08
DE60103136T2 (de) 2004-10-28
US7235658B2 (en) 2007-06-26
EP1263753A1 (de) 2002-12-11
ES2218391T3 (es) 2004-11-16
JP2003525936A (ja) 2003-09-02
US20030153588A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
DE60103136D1 (de) Imidazol derivate als raf kinase inhibitoren
ATE266021T1 (de) Imidazol-2-carbonsäureamid derivate als raf kinase inhibitoren
RU2007110629A (ru) Ингибиторы днк-пк
TW200611907A (en) Fused heterocyclic compound
NO20062633L (no) Pyrazolderivater som proteinkinasemodulatorer
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
EP1259487B8 (de) 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren
EA201170196A1 (ru) Производные бензазепинов и их применение в качестве h3 гистаминовых антагонистов
ATE164575T1 (de) Substituierte aromatische verbindungen als c. amp phosphodiesterase-und tnf-hemmer
EP1724262A4 (de) 1-(2h)-isochinolonderivat
ATE361916T1 (de) Pyrimidine verbindungen
HRP20040429B1 (hr) Derivati sulfonamida, njihova priprema i upotrebakao lijekova
DE60115465D1 (de) Immunoregulierende verbindungen, deren derivate und ihre verwendung
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
ATE403653T1 (de) Pyridin-substituierte furanderivate als raf- kinase inhibitoren
RU2403253C2 (ru) Пуриновые производные для применения в качестве агонистов аденозинового рецептора а-2а
ATE305930T1 (de) Substituierte benzopyran derivate gegen arrhythmie
EA200701780A1 (ru) Противоопухолевое средство
TW200613297A (en) Pyrazole derivatives
UA74341C2 (uk) Похідні борелідину, які інгібують ангіогенез
DE602006010702D1 (de) Homomorpholinoxazolidinone als antibakterielle mittel
DK0504290T3 (da) Inhibitorer af dihydrofylatreduktase fra Pneumocystis carinii
IS7911A (is) Ímídasólafleiður með sækni í alfa 2 viðtakavirkni
ATE483689T1 (de) Pyrazolderivate als modulatoren von proteinkinase
TH96042A (th) สารประกอบเฮเทอโรไซคลิกที่เชื่อมต่อกัน

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties